Schedule of Allocation of Purchase Price (Details) - USD ($)				6 Months Ended
	Jun. 02, 2025	Oct. 11, 2024	Aug. 11, 2023	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Assets and liabilities acquired:
Goodwill				$ 5,878,986		$ 5,878,986
Loss on disposition				$ (1,534,517)
Five Narrow Lane LP [Member]
Business Combination [Line Items]
Common Stock		$ 214,937
NAYA Acquisition Pre-funded Warrants			$ 300,978
Series C-1 Preferred		17,691,000
Series C-2 Preferred		7,457,000
Convertible Debenture		3,934,146
Business acquisition cost		29,598,061
Assets and liabilities acquired:
Cash		472,008
Other current assets		40,747
Goodwill		17,656,707
AP & accrued liabilities		(3,109,039)
Debt		(290,362)
Total assets and liabilities acquired		29,598,061
Five Narrow Lane LP [Member] | Trade Names [Member]
Assets and liabilities acquired:
In process R&D		257,000
Five Narrow Lane LP [Member] | In Process Research and Development [Member]
Assets and liabilities acquired:
In process R&D		$ 14,571,000
NAYA Therapeutics [Member]
Business Combination [Line Items]
Series C-1 Preferred	$ 2,466,810
Business acquisition cost	11,149,596
Assets and liabilities acquired:
Cash	6,569
Other current assets	16,700
Goodwill	3,011,638
AP & accrued liabilities	(4,804,016)
Debt	(374,778)
Loss on disposition	1,534,517
NTI Note Receivable	4,803,175
NTI Series A Preferred	3,879,611
Net assets	12,684,113
NAYA Therapeutics [Member] | Trade Names [Member]
Assets and liabilities acquired:
In process R&D	257,000
NAYA Therapeutics [Member] | In Process Research and Development [Member]
Assets and liabilities acquired:
In process R&D	$ 14,571,000